Di-2-ethylhexylphthalate Contributes to 13 Percent of All Cardiovascular Deaths in Those Aged 55 to 64
By Elana Gotkine HealthDay Reporter
TUESDAY, May 6, 2025 -- Di-2-ethylhexylphthalate (DEHP) contributes to 13.497 percent of all cardiovascular deaths among individuals aged 55 to 64 years, with considerable geographic disparities, according to a study published online April 29 in eBioMedicine.
Sara Hyman, from the New York University Grossman School of Medicine in New York City, and colleagues estimated phthalate-attributable cardiovascular mortality using data from the Institute for Health Metrics and Evaluation and regional DEHP exposure estimates.
The researchers found that an estimated 356,238 deaths globally were attributed to DEHP exposure in 2018, representing 13.497 percent of all cardiovascular deaths among individuals aged 55 to 64 years. Overall, 349,113 of these were attributed to plastic use. There were geographic disparities observed, with the greatest percentage of cardiovascular deaths attributable to DEHP exposure for South Asia and the Middle East (16.807 percent). The largest shares of DEHP-attributable cardiovascular disease deaths were accounted for by the Middle East, South Asia, East Asia, and the Pacific (73.163 percent). DEHP resulted in 10.473 million years of life lost globally.
"These data highlight critical global disparities in loss of life due to plastics pollution," the authors write. "These findings underscore the critical need for enhanced regulatory measures and international cooperation to mitigate the health impacts of phthalates."
One author disclosed ties to industry. Beyond Petrochemicals partially funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-05-07 06:00
Read more

- Linerixibat New Drug Application (NDA) Accepted for Review by the US FDA for Cholestatic Pruritus in Patients with Primary Biliary Cholangitis (PBC)
- Merck’s Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBCL in Phase 2 Portion of waveLINE-003 Trial
- Pheast Therapeutics Receives FDA Fast Track Designation for PHST001 for the Treatment of Ovarian Cancer
- FDA Approves Polypill Widaplik for Hypertension
- An Expert's Guide to Keeping Middle-Age Spread at Bay
- Smartphone App Can Track Huntington's Disease Symptoms
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions